Lund, Sweden, July 2, 2026. Hansa Biopharma AB, “Hansa” (Nasdaq Stockholm: HNSA), today announced that Maria Törnsén, COO and President U.S., Hansa Biopharma, will participate in a fireside chat titled “Don’t Be So Sensitive – Bringing Kidneys to the Over-Sensitized” with Dr. Leonardo Riella, Massachusetts General Hospital, at the Wedbush PacGrow Renal Summit in Boston, at […]
US pivotal trial is a multi-center study evaluating a bioabsorbable hemodialysis vascular access implant across complex hemodialysis patients representing real-world practice > 50% of target enrollment reached across 20 sites in the United States EINDHOVEN, The Netherlands – 2 July, 2026 – Xeltis, a leading developer of transformative implants that enable the natural creation […]
Preclinical data highlight restoration of cognitive, behavioral and synaptic deficits in Fragile X syndrome models Barcelona, Spain – 2 July 2026 – CONNECTA Therapeutics, a clinical-stage biotech company pioneering first-in-class neuroplasticity modulators to address unmet medical needs in central nervous system (CNS) disorders, today announced that it will present a poster, together with the Centre […]
SERB assumes responsibility for the commercialization of Idefirix in transplantation in the EU, UK, Switzerland, Norway, Liechtenstein, Iceland and MENA region The transaction significantly strengthens Hansa’s financial position and enables a robust US launch, subject to US approval of imlifidase Lund, Sweden, July 1, 2026. Hansa Biopharma AB (“Hansa” or “the Company”) (Nasdaq Stockholm: HNSA) and […]
Seven internationally recognized nephrology experts join R1’s Scientific Advisory Board Strengthens scientific and clinical guidance as AP306 advances into global Phase 2b development for the treatment of hyperphosphatemia in chronic kidney disease Board chaired by Glenn M. Chertow, M.D., MPH, Professor of Medicine, Epidemiology and Population Health, and Health Policy at Stanford University School of […]
